Safety, Pharmacokinetics and Antiviral Activity of RV521 Against RSV

• Status: Completed
• Trial end date: 2017-10-31
• Target enrollment: 0
• Participant gender: All

Summary

The main aims of the study are to assess the safety, pharmacokinetics and antiviral activity of multiple doses of RV521 compared to placebo in healthy adult subjects infected with Respiratory Syncytial Virus (RSV) in the Virus Challenge Model

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: ReViral Ltd
• Treatments: Antiviral Agents

Criteria

Inclusion Criteria:

• Age 18 to 45 years, inclusive

• In good health with no history of major medical conditions

• A total body weight ≥ 50 kg and a body mass index (BMI) of >/=18kg/m2 and Exclusion Criteria:

• Evidence of any clinically significant or currently active major medical condition

• Positive for Human Immunodeficiency Virus, active Hepatitis A, B or C test

• Significant nose or nasopharynx abnormalities

• Abnormal lung function

• History or currently active symptoms suggestive of upper or lower respiratory tract infection